Coherus Catapults into Immuno-oncology Field with US$1.8 B Junshi Alliance
By Michelle Liu
Pharma Deals Review: Vol 2021 Issue 2 (Table of Contents)
Published: 8 Feb-2021
DOI: 10.3833/pdr.v2021.i2.2592 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Laying the foundation to its immuno-oncology business, Coherus BioSciences has partnered with Shanghai Junshi Biosciences for the development and commercialisation of Junshi’s anti-PD-1 antibody, toripalimab, in the US and Canada...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS